论文部分内容阅读
GOld等在1965年首先发现癌胚抗原〈CEA〉是结肠癌的特异性抗原。随着对CEA的深入研究,证明在肺癌、乳腺癌等恶性肿瘤其含量也增高、且其含量与肿瘤的消长相平行。我们采用CEA单克隆抗体(McAb)酶免疫法(EIA)对145例肺癌患者进行了血清CEA测定,以探讨CEA检测在肺癌的应用价值。对象和方法一、研究对象1.经组织和/或细胞学检查证实的肺癌患者145例(其中疗前患者71例,疗后患者74例):男97,女48例;年龄24～77岁。2.肺非癌疾病38例:男性26例,女性12例;年龄26～64岁;其中肺炎15例,肺结核6例,支气管扩张6例,肺不张4例,肺气肿7例。3.健康献血员57例:男35例,女22例;年龄20～42岁。二、试剂CEA-EIA(McAb)试药盒由北京生物制品研究所提供,批号85-3,85-6和86-6。
GOld et al. first discovered in 1965 that carcinoembryonic antigen (CEA) is a specific antigen of colon cancer. With the in-depth study of CEA, it is proved that the content of malignant tumors such as lung cancer and breast cancer is also increased, and its content is parallel to the growth and decline of tumors. We used CEA monoclonal antibody (McAb) enzyme immunoassay (EIA) to detect serum CEA in 145 patients with lung cancer to investigate the application of CEA in lung cancer. Subjects and Methods 1. Subjects 1. 145 patients with lung cancer confirmed by histological and/or cytological examination (71 patients before treatment and 74 patients after treatment): 97 males and 48 females; aged 24 to 77 years . 2. Non-cancer lung disease in 38 cases: 26 males and 12 females; aged 26 to 64 years; including 15 cases of pneumonia, 6 cases of pulmonary tuberculosis, 6 cases of bronchiectasis, 4 cases of pulmonary atelectasis, 7 cases of emphysema. 3. 57 healthy blood donors: 35 males and 22 females; aged 20 to 42 years. II. Reagents CEA-EIA (McAb) reagent kits were provided by Beijing Institute of Biological Products, batch numbers 85-3, 85-6 and 86-6.